エピソード性運動失調治療の世界市場レポート 2025年

エピソード性運動失調治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で152億1,000万米ドルに成長します。予測期間の成長は、遺伝学的検査へのアクセスの増加、遺伝カウンセリングサービスへの需要の高まり、臨床試験数の増加、患者登録数の増加、希少疾患バイオバンクへの投資の増加などに起因すると考えられます。予測期間における主な動向としては、技術の進歩、個別化医療、遠隔医療、幹細胞治療、遠隔リハビリテーションサービスなどが挙げられます。

神経疾患の有病率の増加は、エピソード性運動失調治療市場の拡大を促進すると予想されます。神経疾患には、脳、脊髄、脳神経および末梢神経、自律神経系、神経根、神経筋接合部、筋肉を含む中枢神経系および末梢神経系に影響を及ぼす疾患が含まれます。高齢化、遺伝的素因、感染症などの要因が、神経疾患の罹患率上昇に寄与しています。エピソード性運動失調治療は、断続的な協調運動や平衡感覚の喪失を伴う症状への対応と、その管理の強化を目指しています。例えば、2022年4月、ベルギーを拠点とする非営利団体European Brain Councilは、認知症（進行性の神経疾患）が2022年に欧州で1,050万人に影響を与え、2050年には1,870万人に増加するという予測を報告しています。その結果、神経疾患の有病率の上昇がエピソード性運動失調治療市場に拍車をかけています。

エピソード性運動失調治療市場の主要企業は、フリードライヒ失調症（FA）治療などの革新的ソリューションの開発を優先し、患者の予後を改善し、この稀な神経疾患のアンメットニーズに対応しています。エピソード性運動失調症（EA）は、運動失調の散発的なエピソードと随意筋協調運動の欠如を特徴とし、エピソードの期間、頻度、重症度は様々です。例えば、2024年2月、米国のバイオテクノロジー企業Biogen Inc.は、フリードライヒ失調症（FA）の治療薬としてSKYCLARYS（omaveloxolone）の承認を発表しました。オマベロキソロンは、FAに関連する根本的なミトコンドリア機能障害を標的とし、単に症状を緩和するだけでなく、疾患の進行を変える可能性があります。この治療薬は強力な転写調節因子として機能し、ミトコンドリア機能と細胞エネルギー産生の回復を助ける。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エピソード性運動失調治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエピソード性運動失調治療市場：成長率分析
• 世界のエピソード性運動失調治療市場の実績：規模と成長, 2019-2024
• 世界のエピソード性運動失調治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界エピソード性運動失調治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエピソード性運動失調治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毛細血管拡張性運動失調症
• 発作性運動失調症
• 脊髄小脳失調症
• フリードライヒ運動失調症
• その他のタイプ
• 世界のエピソード性運動失調治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• レボドパ
• プラミペキソール
• ベンラファキシン
• その他の治療法
• 世界のエピソード性運動失調治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のエピソード性運動失調治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接入札
• 小売売上高
• その他の流通チャネル
• 世界のエピソード性運動失調治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ヘルスケア
• その他のエンドユーザー
• 世界のエピソード性運動失調治療市場毛細血管拡張性運動失調症の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節治療
• 抗酸化療法
• 遺伝子治療
• 世界のエピソード性運動失調治療市場発作性運動失調症の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤（アセタゾラミド、フェニトイン）
• 対症療法（ベンゾジアゼピン）
• 世界のエピソード性運動失調治療市場脊髄小脳失調症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療（抗うつ薬、抗けいれん薬）
• 理学療法
• 遺伝子治療
• 世界のエピソード性運動失調治療市場フリードライヒ運動失調症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗酸化療法（イデベノン）
• 遺伝子治療
• 治療（心臓薬、理学療法）
• 世界のエピソード性運動失調治療市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療（筋弛緩薬、ドパミン作動薬）
• 支持療法（理学療法、作業療法）

第7章 地域別・国別分析

• 世界のエピソード性運動失調治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエピソード性運動失調治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エピソード性運動失調治療市場：競合情勢
• エピソード性運動失調治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Banner Health
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• UCB S.A.
• Ipsen
• BioMarin Pharmaceutical Inc.
• Neurocrine Biosciences Inc.
• PTC Therapeutics Inc.
• Kissei Pharmaceutical Co. Ltd.
• Catalyst Pharmaceuticals Inc.
• Design Therapeutics Inc.
• Larimar Therapeutics Inc.
• Voyager Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エピソード性運動失調治療市場2029：新たな機会を提供する国
• エピソード性運動失調治療市場2029：新たな機会を提供するセグメント
• エピソード性運動失調治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for episodic ataxia encompasses medical strategies aimed at managing and alleviating the symptoms of this rare neurological disorder, which features intermittent episodes of poor coordination, balance issues, and sometimes vertigo. The approach includes medications, therapies, and lifestyle changes designed to control symptoms and enhance the quality of life for those affected.

The main treatment categories for episodic ataxia include ataxia telangiectasia, episodic ataxia, spinocerebellar ataxia, and Friedreich's ataxia. Ataxia telangiectasia is a rare genetic disorder impacting both the nervous and immune systems, leading to progressive movement difficulties, an elevated risk of cancer, and other health concerns. Treatments for this condition may involve medications such as levodopa, pramipexole, and venlafaxine, administered through various methods including oral and parenteral routes. Distribution channels for these treatments include direct tenders and retail sales, serving different end users through these channels.

The episodic ataxia treatment market research report is one of a series of new reports from The Business Research Company that provides episodic ataxia treatment market statistics, including episodic ataxia treatment industry global market size, regional shares, competitors with an episodic ataxia treatment market share, detailed episodic ataxia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the episodic ataxia treatment industry. This episodic ataxia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The episodic ataxia treatment market size has grown strongly in recent years. It will grow from $11.07 billion in 2024 to $11.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to an increasing understanding of genetic causes, increasing funding for rare disease research, increasing availability of specialized clinics, rising awareness of personalized medicine, and growth in clinical trial participation.

The episodic ataxia treatment market size is expected to see strong growth in the next few years. It will grow to $15.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing genetic testing accessibility, rising demand for genetic counseling services, growing number of clinical trials, increasing number of patient registries, and increasing investment in rare disease biobanks. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, stem cell therapy, and telerehabilitation services.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the episodic ataxia treatment market. Neurological disorders encompass diseases affecting the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles. Factors such as an aging population, genetic predispositions, and infectious diseases contribute to the rising incidence of neurological disorders. Episodic ataxia treatment aims to address symptoms and enhance the management of conditions involving intermittent coordination and balance loss. For example, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that Dementia (a progressive neurological disorder) impacted 10.5 million people in Europe in 2022, with projections indicating an increase to 18.7 million by 2050. Consequently, the rising prevalence of neurological disorders is fueling the episodic ataxia treatment market.

Leading companies in the episodic ataxia treatment market are prioritizing the development of innovative solutions, such as treatments for Friedreich's ataxia (FA), to improve patient outcomes and address the unmet needs of this rare neurological condition. Episodic ataxia (EA) is characterized by sporadic episodes of ataxia and a lack of voluntary muscle coordination, with episodes varying in duration, frequency, and severity. For instance, in February 2024, Biogen Inc., a US-based biotechnology company, announced the approval of SKYCLARYS (omaveloxolone) for treating Friedreich's ataxia (FA). Omaveloxolone targets the underlying mitochondrial dysfunction associated with FA, potentially altering disease progression rather than merely alleviating symptoms. The therapy functions as a potent transcriptional modulator, aiding in the restoration of mitochondrial function and cellular energy production.

In November 2022, Kriya Therapeutics Inc., a US-based biopharmaceutical company, acquired Redpin Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly bolster Kriya Therapeutics' neurology pipeline by incorporating Redpin's innovative treatments for neurological disorders into its existing gene therapy portfolio. Redpin Therapeutics Inc. is a US-based company dedicated to developing treatments for various neurological and neurodegenerative disorders, including episodic ataxia.

Major companies operating in the episodic ataxia treatment market are Pfizer Inc., AbbVie Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Merck KGaA, Banner Health, Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB S.A., Ipsen, BioMarin Pharmaceutical Inc., Neurocrine Biosciences Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Catalyst Pharmaceuticals Inc., Design Therapeutics Inc., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Capsida Biotherapeutics Inc., Adverum Biotechnologies Inc., CRISPR Therapeutics AG

North America was the largest region in the episodic ataxia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the episodic ataxia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the episodic ataxia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The episodic ataxia treatment market consists of revenues earned by entities by providing services such as genetic counseling, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The episodic ataxia treatment market also includes sales of antiepileptic drugs, beta-blockers, genetic testing kits, and wearable health monitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Episodic Ataxia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on episodic ataxia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for episodic ataxia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The episodic ataxia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Ataxia telangiectasia; Episodic ataxia; Spinocerebellar ataxia; Friedreich's ataxia; Other Types
• 2) By Treatment: Medications; Levodopa; Pramipexole; Venlafaxine; Other Treatments
• 3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
• 4) By Distribution Channel: Direct Tender; Retail Sales; Other Distribution Channels
• 5) By End User: Hospital; Clinics; Home Healthcare; Other End Users

Subsegments

• 1) By Ataxia Telangiectasia: Neurological Complications; Immunodeficiency; Cancer Susceptibility
• 2) By Episodic Ataxia: Type 1 (EA1); Type 2 (EA2); Other Subtypes
• 3) By Spinocerebellar Ataxia: Type 1 (SCA1); Type 2 (SCA2); Type 3 (SCA3); Type 6 (SCA6); Type 7 (SCA7); Type 17 (SCA17); Other Types
• 4) By Friedreich's Ataxia: Early-onset Friedreich's Ataxia; Late-onset Friedreich's Ataxia; Other Types
• 5) By Other Treatments: Supportive Care (Physical Therapy, Occupational Therapy); Symptomatic Treatment (Muscle Relaxants, Dopaminergic Medications)
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Episodic Ataxia Treatment Market Characteristics

3. Episodic Ataxia Treatment Market Trends And Strategies

4. Episodic Ataxia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Episodic Ataxia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Episodic Ataxia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Episodic Ataxia Treatment Market Growth Rate Analysis
• 5.4. Global Episodic Ataxia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Episodic Ataxia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Episodic Ataxia Treatment Total Addressable Market (TAM)

6. Episodic Ataxia Treatment Market Segmentation

• 6.1. Global Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ataxia Telangiectasia
• Episodic Ataxia
• Spinocerebullar Ataxia
• Friedreich's Ataxia
• Other Types
• 6.2. Global Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Levodopa
• Pramipexole
• Venlafaxine
• Other Treatments
• 6.3. Global Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Episodic Ataxia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Retail Sales
• Other Distribution Channels
• 6.5. Global Episodic Ataxia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Home Healthcare
• Other End Users
• 6.6. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Ataxia Telangiectasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulatory Treatments
• Antioxidant Therapy
• Gene Therapy
• 6.7. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Episodic Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications (Acetazolamide, Phenytoin)
• Symptomatic Treatments (Benzodiazepines)
• 6.8. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Spinocerebellar Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic Treatment (Antidepressants, Anticonvulsants)
• Physical Therapy
• Gene Therapy
• 6.9. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Friedreich's Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antioxidant Therapy (Idebenone)
• Gene Therapy
• Symptomatic Treatment (Cardiac Medications, Physical Therapy)
• 6.10. Global Episodic Ataxia Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic Treatment (Muscle Relaxants, Dopaminergic Medications)
• Supportive Care (Physical Therapy, Occupational Therapy)

7. Episodic Ataxia Treatment Market Regional And Country Analysis

• 7.1. Global Episodic Ataxia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Episodic Ataxia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Episodic Ataxia Treatment Market

• 8.1. Asia-Pacific Episodic Ataxia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Episodic Ataxia Treatment Market

• 9.1. China Episodic Ataxia Treatment Market Overview
• 9.2. China Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Episodic Ataxia Treatment Market

• 10.1. India Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Episodic Ataxia Treatment Market

• 11.1. Japan Episodic Ataxia Treatment Market Overview
• 11.2. Japan Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Episodic Ataxia Treatment Market

• 12.1. Australia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Episodic Ataxia Treatment Market

• 13.1. Indonesia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Episodic Ataxia Treatment Market

• 14.1. South Korea Episodic Ataxia Treatment Market Overview
• 14.2. South Korea Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Episodic Ataxia Treatment Market

• 15.1. Western Europe Episodic Ataxia Treatment Market Overview
• 15.2. Western Europe Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Episodic Ataxia Treatment Market

• 16.1. UK Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Episodic Ataxia Treatment Market

• 17.1. Germany Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Episodic Ataxia Treatment Market

• 18.1. France Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Episodic Ataxia Treatment Market

• 19.1. Italy Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Episodic Ataxia Treatment Market

• 20.1. Spain Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Episodic Ataxia Treatment Market

• 21.1. Eastern Europe Episodic Ataxia Treatment Market Overview
• 21.2. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Episodic Ataxia Treatment Market

• 22.1. Russia Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Episodic Ataxia Treatment Market

• 23.1. North America Episodic Ataxia Treatment Market Overview
• 23.2. North America Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Episodic Ataxia Treatment Market

• 24.1. USA Episodic Ataxia Treatment Market Overview
• 24.2. USA Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Episodic Ataxia Treatment Market

• 25.1. Canada Episodic Ataxia Treatment Market Overview
• 25.2. Canada Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Episodic Ataxia Treatment Market

• 26.1. South America Episodic Ataxia Treatment Market Overview
• 26.2. South America Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Episodic Ataxia Treatment Market

• 27.1. Brazil Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Episodic Ataxia Treatment Market

• 28.1. Middle East Episodic Ataxia Treatment Market Overview
• 28.2. Middle East Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Episodic Ataxia Treatment Market

• 29.1. Africa Episodic Ataxia Treatment Market Overview
• 29.2. Africa Episodic Ataxia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Episodic Ataxia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Episodic Ataxia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Episodic Ataxia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Episodic Ataxia Treatment Market Competitive Landscape
• 30.2. Episodic Ataxia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Episodic Ataxia Treatment Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Merck KGaA
• 31.3. Banner Health
• 31.4. Astellas Pharma Inc.
• 31.5. Daiichi Sankyo Company Limited
• 31.6. UCB S.A.
• 31.7. Ipsen
• 31.8. BioMarin Pharmaceutical Inc.
• 31.9. Neurocrine Biosciences Inc.
• 31.10. PTC Therapeutics Inc.
• 31.11. Kissei Pharmaceutical Co. Ltd.
• 31.12. Catalyst Pharmaceuticals Inc.
• 31.13. Design Therapeutics Inc.
• 31.14. Larimar Therapeutics Inc.
• 31.15. Voyager Therapeutics Inc.

32. Global Episodic Ataxia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Episodic Ataxia Treatment Market

34. Recent Developments In The Episodic Ataxia Treatment Market

35. Episodic Ataxia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Episodic Ataxia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Episodic Ataxia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Episodic Ataxia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer